At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 139 enrolled
Drug / intervention
Timolol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study Evaluating The Efficacy And Safety Of Latanoprost And Timolol In Pediatric Subjects With Glaucoma.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Jul 16, 2008·Updated Feb 3, 2021
In Brief
A Phase 3 clinical trial evaluating Timolol and latanoprost for Glaucoma. Completed, enrolled 139 participants across 48 sites in 20 countries.
Detailed Summary
To assess the effectiveness of latanoprost 0.005% ophthalmic solution dosed once-daily and timolol 0.5% dosed twice-daily in paediatric subjects of 18 years of age or under who are diagnosed with glaucoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesBelgium, Colombia, Czechia, France, Germany, India, Italy, Philippines, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, South Africa, Spain, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2008
First PostedJul 2008
Primary CompletionNov 2009
TodayJul 2026
First PostedJul 16, 2008
Enrollment StartJul 1, 2008
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 18.0 years ago
Interventions
Timololdrug
Timolol 0.5% dosed twice-daily
latanoprostdrug
Latanoprost 0.005% ophthalmic solution dosed once-daily